Evaluation of serum DNA integrity as a screening and prognostic tool in patients with hepatitis C virus-related hepatocellular carcinoma

International Journal of Biological Markers

Volumn 25, Issue 2, 2010, Pages 79-86

  El Shazly, Sherien F ^a   Eid, Manal A ^a   El Sourogy, Hesham A ^a   Attia, Gehan F ^a   Ezzat, Sherif A ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

DNA integrity; HCV; HCV related HCC; Real time PCR; Total circulating DNA

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DNA; PROTHROMBIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALU SEQUENCE; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BASE PAIRING; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CANCER SCREENING; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; DNA CONTENT; DNA EXTRACTION; DNA SCREENING; EARLY DIAGNOSIS; ECHOGRAPHY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTHROMBIN TIME; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; AGED; BLOOD; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; CHEMISTRY; COMPLICATION; DNA DAMAGE; EVALUATION STUDY; GENETICS; HEPACIVIRUS; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PROCEDURES; SERUM;

HEPATITIS C VIRUS;

AGED; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DNA; DNA DAMAGE; EARLY DETECTION OF CANCER; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SERUM;

EID: 77954890421     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460081002500204     Document Type: Article

References (32)

1. Goldman R, Ressom HW, Abdel-Hamid M, et al. Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum. Carcinogenesis 2007; 28: 2149-53.
2. Mizokami M, Tanaka Y. Tracing the evolution of hepatitis C virus in the United States, Japan, and Egypt by using the molecular clock. Clin Gastroenterol Hepatol 2005; 3: 82-5.
3. Deuffic-Burban S, Wong JB, Valleron AJ, Costagliola D, Delfraissy JF, Poynard T. Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. J Hepatol 2006; 44: 455-61. (Pubitemid 43227869)
4. Ezzat S, Abdel-Hamid M, Eissa SA, et al. Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt. Int J Hyg Environ Health 2005; 208: 329-39.
5. Hassan MM, Zaghloul AS, El-Serag HB, et al. The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. J Clin Gastroenterol 2001; 33: 123-6.
6. Perz JF, Alter MJ. The coming wave of HCV-related liver disease: dilemmas and challenges. J Hepatol 2006; 44: 441-3.
7. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40: 225-35.
8. Marrero JA. Screening tests for hepatocellular carcinoma. Clin Liver Dis 2005; 9: 235-51.
9. Gupta S, Bent S, Kohlwes J. Test characteristics of alphafetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 2003; 139: 46-50.
10. Taback B, Hoon DS. Circulating nucleic acids in plasma and serum: Past, present and future. Curr Opin Mol Ther 2004; 6: 273-8. (Pubitemid 38997128)
11. Fujimoto A, O'Day SJ, Taback B. Allelic imbalance on 12q22-23 in serum circulating DNA of melanoma patients predicts disease outcome. Cancer Res 2004; 64: 4085-8.
12. Gal S, Fidler C, Lo YM. Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR. Br J Cancer 2004; 90: 1211-5. (Pubitemid 38496815)
13. Giacona MB, Ruben GC, Iczkowski KA. Cell-free DNA in human blood plasma: Length measurements in patients with pancreatic cancer and healthy controls. Pancreas 1988; 17: 89-97.
14. Wyllie AH: Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980; 284: 555-6.
15. Jahr S, Hentze H, Englisch S. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001; 61: 1659-65. (Pubitemid 34292602)
16. Li CN, Hsu HL, Wu TL, Tsao KC, Sun CF, Wu JT. Cell-free DNA is released from tumor cells upon cell death: a study of tissue cultures of tumor cell lines. J Clin Lab Anal 2003; 17: 103-7.
17. Anker P, Stroun M, Maurice PA. Spontaneous extracellular synthesis of DNA released by human blood lymphocytes. Cancer Res 1976; 36: 2832-9.
18. Wang BG, Huang HY, Chen YC. Increased plasma DNA integrity in cancer patients. Cancer Res 2003; 63: 3966-8.
19. Chan KC, Leung SF, Yeung SW, Chan AT, Lo YM. Persistent aberrations in circulating DNA integrity after radiotherapy are associated with poor prognosis in nasopharyngeal carcinoma patients. Clin Cancer Res 2008; 14: 4141-5.
20. Gu Z, Wang H, Nekrutenko A. Densities, length proportions, and other distributional features of repetitive sequences in the human genome estimated from 430 megabases of genomic sequence. Gene 2000; 259: 81-8. (Pubitemid 32119239)
21. Lander ES, Linton LM, Birren B. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
22. Umetani M, Giuliano AE, Hiramatsu SH, et al. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol 2006; 24: 4270-6.
23. Umetani N, Hiramatsu S, Hoon DSB. Higher amount of free circulating DNA in serum than in plasma is not mainly caused by contaminated extraneous DNA during separation. Ann N Y Acad Sci 2006; 1075: 299-307. (Pubitemid 44532797)
24. Chan KC, Yeung SW, Lui WB, Rainer TH, Lo YM. Effects of preanalytical factors on the molecular size of cell-free DNA in blood. Clin Chem 2005; 51: 781-4.
25. Taback B, O'Day SJ, Hoon DS. Quantification of circulating DNA in the plasma and serum of cancer patients. Ann N Y Acad Sci 2004; 1022: 17-24. (Pubitemid 38951576)
26. Thijssen MA, Swinkels DW, Ruers TJ, de Kok JB. Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases. Anticancer Res 2002; 22: 421-5.
27. Iizuka N, Sakaida I, Moribe T, et al. Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma. Anticancer Res 2006; 26: 4713-9.
28. Umetani N, Kim J, Hiramatsu S, et al. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem 2006; 52: 1062-9.
29. Chan KC, Zhang J, Hui AB, et al. Size distributions of maternal and fetal DNA in maternal plasma. Clin Chem 2004; 50: 88-92. (Pubitemid 38125703)
30. Ren N, Ye QH, Qin LY, Bo-Zhang BH, Liu YK, Tang ZY. Circulating DNA level is negatively associated with the long-term survival of hepatocellular carcinoma patients. World J Gastroenterol 2006; 12: 3911-4. (Pubitemid 44028408)
31. Morimoto M, Numata K, Sugimori K, et al. Successful initial ablation therapy contributes to survival in patients with hepatocellular carcinoma. World J Gastroenterol 2007; 13: 1003-9.
32. Zhao WH, Feng YZ, Ma ZM, Zhou XR. Study on prognostic factors for hepatocellular carcinoma after resection by Cox proportional hazard. Zhonghua Putong Waike Zazhi 2001; 16: 472-4.